Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

128 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-02

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question\[s\] it aims to answer are:

* Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy?
* Is treatment with psilocybin and therapy safe for participants?

Participants will

* Attend 13 study visits
* Take part in therapy sessions including 2 treatment sessions with either psilocybin or placebo
* Record their daily alcohol consumption on study specific device

Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

NCT06349083

Alcohol Use Disorder

RECRUITING PHASE2

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

NCT05995769

Alcohol Use Disorder Alcoholism

RECRUITING PHASE2

Psilocybin in Alcohol Use Disorder With Comorbid Depression

NCT06235411

COMPLETED NA

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293

Alcohol Dependence

COMPLETED PHASE2

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

NCT06405607

Alcohol Use Disorder Alcohol Dependence Alcohol Abuse

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Psilocybin

2 oral doses of 25mg psilocybin capsules

Group Type EXPERIMENTAL

Psilocybin

Intervention Type DRUG

Psilocybin and psychotherapy

Placebo

2 oral doses of placebo (microcrystalline cellulose) capsules

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo and psychotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Psilocybin

Psilocybin and psychotherapy

Intervention Type DRUG

Placebo

Placebo and psychotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe diagnosis of AUD as measured by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria using Structured Clinical Interview for DSM-5 by the investigator.
* Expressed a wish to reduce or stop alcohol consumption.
* Generally healthy with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, electrocardiogram, urine analysis, and urine toxicology.

Exclusion Criteria

* Diagnosed with or having a family history of any of the following concomitant psychiatric disorders: schizophrenia or prodromal symptoms, any bipolar disorder, obsessive compulsive disorder, or other psychotic episode. Recent (within last 12 months) diagnosis of a major depressive disorder (MDD) (HAM-D score \>19), treatment resistant depression (TRD), post-traumatic stress disorder (PTSD), panic disorder, or eating disorders.
* Subjects deemed unfit for psilocybin-assisted therapy based on the assessments made during psychotherapy sessions prior to the first psilocybin-assisted psychotherapy session.
* History of hallucinogen use disorder, or any use in the past 1 year, or \>25 lifetime uses.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No